Patents by Inventor C. Foster

C. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
    Publication number: 20030185765
    Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.
    Type: Application
    Filed: March 14, 2003
    Publication date: October 2, 2003
    Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
  • Method for treating inflammation using soluble receptors to interleukin-20
    Patent number: 6610286
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: August 26, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Donald C. Foster, Wenfeng Xu, James D. Kelly, Hal Blumberg, Yasmin A. Chandrasekher
  • Methods of using zalpha11 ligand
    Patent number: 6605272
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: August 12, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Making leadframe semiconductor packages with stacked dies and interconnecting interposer
    Patent number: 6603072
    Abstract: In a leadframe type of semiconductor package, the internal electrical interconnectability of and signal routing between multiple dies laminated in a stack with the die paddle of the leadframe is substantially enhanced by laminating an “interposer” in the stack. The interposer comprises a dielectric layer and a metallic layer patterned to include wire bonding pads arrayed around the periphery of a surface thereof, and circuit traces interconnecting selected ones of the wire bonding pads in a single plane across the horizontal span of the interposer. In packages having multiple dies and relatively few leads, the bonding pads and circuit traces can be flexibly arranged on the interposer by the package designer to substantially increase the number and routings of internal electrical interconnections otherwise possible between the dies and between the dies and the leads of the package.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: August 5, 2003
    Assignee: Amkor Technology, Inc.
    Inventors: Donald C. Foster, David A. Zoba
  • Metal silicide gate transistors
    Patent number: 6602781
    Abstract: A method for implementing a self-aligned metal silicide gate is achieved by confining a metal within a recess overlying a channel and annealing to cause metal and its overlying silicon to interact to form the self-aligned metal silicide gate. A gate dielectric layer formed of oxynitride or a nitride/oxide stack is formed on the bottom and sidewalls of the recess prior to depositing the silicon. The metal is removed except for the portion of the metal in the recess. A planarization step is performed to remove the remaining unreacted silicon by chemical mechanical polishing until no silicon is detected.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: August 5, 2003
    Assignee: Advanced Micro Devices, Inc.
    Inventors: Qi Xiang, Paul R. Besser, Matthew Buynoski, John C. Foster, Paul L. King, Eric N. Paton
  • Protease-activated receptor PAR4 (ZCHEMR2)
    Publication number: 20030143218
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for PAR4, a novel member of the protease-activated receptor family. The polypeptides, and polynucleotides encoding them, mediate biological responses and/or cellular signaling in response to proteases. Protease cleavage of PAR4 exposes a PAR4 extracellular amino terminal portion that serves as a ligand for the PAR4 receptor. PAR4 may be used as a target in drug screening, and further used to identify proteinaceous or non-proteinaceous PAR4 agonists and antagonists. The present invention also includes antibodies to the PAR4 polypeptides.
    Type: Application
    Filed: June 28, 2002
    Publication date: July 31, 2003
    Inventors: Wenfeng Xu, Scott R. Presnell, David P. Yee, Donald C. Foster
  • Liquid crystal forms of cyclosporin
    Publication number: 20030130176
    Abstract: This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.
    Type: Application
    Filed: May 29, 2002
    Publication date: July 10, 2003
    Inventors: David B. Bennett, Kirsten M. Cabot, Linda C. Foster, David Lechuga-Ballesteros, John S. Patton, Trixie K. Tan
  • Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
    Publication number: 20030129141
    Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.
    Type: Application
    Filed: January 31, 2003
    Publication date: July 10, 2003
    Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
  • Stable glassy state powder formulations
    Patent number: 6589560
    Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: July 8, 2003
    Assignee: Nektar Therapeutics
    Inventors: Linda C. Foster, Mei-chang Kuo, Shelia R. Billingsley
  • Novel cytokine zalpha11 ligand
    Publication number: 20030125524
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: November 15, 2002
    Publication date: July 3, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Powered pharmaceutical formulations having improved dispersibility
    Patent number: 6582729
    Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: June 24, 2003
    Assignee: Naktar Therapeutics
    Inventors: Mohammad Eljamal, John S. Patton, Linda C. Foster, Robert M. Platz
  • TESTIS-SPECIFIC RECEPTOR
    Publication number: 20030100047
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in testis cells. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.
    Type: Application
    Filed: June 4, 1998
    Publication date: May 29, 2003
    Inventors: JAMES W. BAUMGARTNER, THERESA M. FARRAH, DONALD C. FOSTER, FRANK J. GRANT, PATRICK J. O'HARA
  • TESTIS-SPECIFIC RECEPTOR
    Publication number: 20030100046
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in testis cells. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.
    Type: Application
    Filed: March 12, 1997
    Publication date: May 29, 2003
    Inventors: JAMES W. BAUMGARTNER, THERESA M. FARRAH, DONALD C. FOSTER, FRANK J. GRANT, PATRICK J. O'HARA
  • Process for forming fully silicided gates
    Patent number: 6562718
    Abstract: A method of forming a fully silicidized gate of a semiconductor device includes forming silicide in active regions and a portion of a gate. A shield layer is blanket deposited over the device. The top surface of the gate electrode is then exposed. A refractory metal layer is deposited and annealing is performed to cause the metal to react with the gate and fully silicidize the gate, with the shield layer protecting the active regions of the device from further silicidization to thereby prevent spiking and current leakage in the active regions.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: May 13, 2003
    Assignee: Advanced Micro Devices, Inc.
    Inventors: Qi Xiang, Ercan Adem, Jacques J. Bertrand, Paul R. Besser, Matthew S. Buynoski, John C. Foster, Paul L. King, George J. Kluth, Minh V. Ngo, Eric N. Paton, Christy Mei-Chu Woo
  • Multiple die lead frame package with enhanced die-to-die interconnect routing using internal lead trace wiring
    Patent number: 6552416
    Abstract: A multiple die package is formed, which allows multiple die to be interconnected using internal leads or traces from a lead frame. A plurality of slots in the paddle area of the lead frame are created which define the internal signal traces. Then the outer portions of the die paddle area of the lead frame are removed or trimmed to isolate the internal traces from each other and form a plurality of individual internal leads. Multiple die, either stacked, in a planar array, or a combination of the two, are connected to selected internal leads, such as by wire bonding, to form the desired die-to-die interconnections for routing signals between die without interfering with normal wire bond fan-out. A tape can be adhered to the interior portion of the die paddle area prior to trimming to hold the internal traces in place and leave the ends of the traces exposed for wire bonding to the die.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: April 22, 2003
    Assignee: Amkor Technology, Inc.
    Inventor: Donald C. Foster
  • Methods and compositions for the dry powder formulation of interferons
    Publication number: 20030072718
    Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.
    Type: Application
    Filed: September 18, 2002
    Publication date: April 17, 2003
    Inventors: Robert M. Platz, Shigenobu Kimura, Yu-Jchiro Satoh, Linda C. Foster
  • Methods and compositions for the dry powder formulation of interferon
    Publication number: 20030035778
    Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.
    Type: Application
    Filed: September 17, 2002
    Publication date: February 20, 2003
    Inventors: Robert Platz, Shigenobu Kimura, Yu-Ichiro Satoh, Linda C. Foster
  • Dispersible antibody compositions and methods for their preparation and use
    Patent number: 6514496
    Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: February 4, 2003
    Assignee: Inhale Therapeutic Systems, Inc.
    Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
  • Methods and compositions for the dry powder formulation of interferons
    Patent number: 6479049
    Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: November 12, 2002
    Assignee: Inhale Therapeutic Systems, Inc.
    Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
  • DNA sequence coding for protein C
    Patent number: RE37958
    Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: January 7, 2003
    Assignee: Board of Regents of the University of Washington
    Inventors: Donald C. Foster, Earl W. Davie